Die folgenden Informationen sind nur auf Englisch verfügbar:
BioFIT will be held in-person in Marseille, France, on Tuesday, December 12th and Wednesday, December 13th, 2023 and will continue online, for digital meetings, on Friday, December 15th.
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.
Projekt - CEO Matchmaking
You are a bioentrepreneur seeking new challenges or you are looking for a passionate CEO to lead your project?
If so, the Project - CEO matchmaking is made for you!
As talented CEOs are frequently sought-after by many players in the biotech industry, the Project – CEO matchmaking activity aims to connect representatives of emerging start-ups, technology transfer offices, incubators, and investing networks with CEOs and aspiring CEOs.
Find the perfect match:
• Any incubator, technology transfer entity or scientific founder looking for an entrepreneur to lead their innovative projects is welcome to participate in the matchmaking activity to meet with qualified candidates!
You will be visible on the partnering platform, to be contacted by potential CEOs.
• If you are a bioentrepreneur looking for a new project to undertake:
Projects looking for a CEO will be visible on the platform and easily identifiable.
Get inspired:
Having the right team is essential for the development of a biotech project. The Project – CEO matchmaking activity also offers a conference session to get inspired and explore the best ways to find the right talents for a successful project.
Conferences
Steered by its prestigious committee, the BioFIT conference programme is shaped to correspond to the interests of every player in the sector and to meet the expectations of its stakeholders, whose sharp minds operate in the fast-paced Life Sciences sector. The 2023 programme is rooted in four custom- made tracks, addressing the right funding sources for early-stage innovation, best practices in academia-industry R&D collaborations, winning ways to nurture early-stage assets and animal health highlights.
R&D dating for animal health & innovation
BioFIT 2023 hosts the 9th edition of the “R&D dating for Animal Health and Innovation” business convention, at the initiative of the French association for the animal healthcare industry (SIMV).
Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate highlevel exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups). By enabling face-to-face encounters, the event enhances the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.
Plenary session
Biopharma industry has been facing uncertainties in 2023: What is the impact for early-stage partnering strategies?
In a global landscape marked by geopolitical complexities including inflation, conflicts, energy price fluctuations, and financial strains, investment opportunities and innovation dynamics have been challenged. As the industry navigates through a changing landscape, this session will explore how these uncertainties are shaping early-stage investment trends and consequently, strategies to forge successful partnerships.
What are the main current issues and opportunities in terms of financing and partnering in the EU biotech ecosystem compared to the US? Has the availability of capital really been affected at the seed and series A stages? Are there any emerging trends or innovative approaches in early-stage collaborations that have emerged as a response? What are the impacts on the negotiation and terms of early-stage partnerships? How are biotech start-ups and pharma companies making the most of the current reality? What is the outlook for life sciences dealmaking in 2024?
Pitch sessions
Start-up Slams
The Start-up Slams are a great opportunity for young companies (and particularly for start-ups seeking to raise a seed or a Series A financing round) to showcase their project in front of potential partners and investors.
Collaborative and licensing opportunity presentations
The Collaborative and Licensing Opportunity Presentations enable TTOs, universities, research institutes and companies to showcase their early-stage technologies in front of potential partners, in order to entail a collaborative project and/or a licensing deal.
Animal Health Presentations
The Animal Health Presentations allow young companies, TTOs, universities, research institutes and companies to showcase their innovative project in front of potential partners and investors in the Animal Health sector.
